US Spurns Eli Lilly's Bid To Prod Canada On Drug Patents
The Office of the U.S. Trade Representative on Wednesday resisted pressure from members of Congress to put additional scrutiny on Canada's intellectual property rights enforcement, dealing a blow to Eli Lilly...To view the full article, register now.
Already a subscriber? Click here to view full article